SCHEMBL14050976

SCHEMBL14050976

Clc1cc(CC2CCOC2)nc2c(Br)cnn12

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PIK3CA P42336 3/20 0.35
▸ GABRP O00591 1/20 0.34
▸ GABRD O14764 1/20 0.34
▸ GABRA1 P14867 1/20 0.34
▸ GABRB1 P18505 1/20 0.34
▸ GABRG2 P18507 1/20 0.34
▸ GABRB3 P28472 1/20 0.34
▸ GABRA5 P31644 1/20 0.34
▸ GABRA3 P34903 1/20 0.34
▸ GABRA2 P47869 1/20 0.34
▸ GABRB2 P47870 1/20 0.34
▸ GABRA4 P48169 1/20 0.34
▸ GABRE P78334 1/20 0.34
▸ GABRA6 Q16445 1/20 0.34
▸ GABRG1 Q8N1C3 1/20 0.34
▸ GABRG3 Q99928 1/20 0.34
▸ GABRQ Q9UN88 1/20 0.34
▸ NLRP3 Q96P20 1/20 0.33
▸ GSK3B P49841 7/20 0.33
▸ CDK2 P24941 4/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12953384 0.83 GSK3B (0.40) GSK3BCDK2CHEK1CCNA2CCNA1
SCHEMBL12953645 0.77 CDK2 (0.43) PIK3CAGSK3BCDK2CHEK1CCNA2
SCHEMBL17182817 0.74 GSK3B (0.39) GSK3BCDK2
SCHEMBL17182815 0.74 GSK3B (0.39) GSK3BCDK2
SCHEMBL17182832 0.74 GSK3B (0.39) GSK3BCDK2
SCHEMBL12953608 0.74 GSK3B (0.45) PIK3CAGSK3BCDK2CHEK1CCNA2
SCHEMBL17182928 0.73 PDE4D (0.37) GSK3BCDK2CHEK1CCNA2CCNA1
SCHEMBL26871203 0.72 CCNT1 (0.36) CDK2CCNA2CCNA1MAPKAPK2
SCHEMBL12953210 0.72 GSK3B (0.52) GSK3BCDK2CHEK1CCNA2CCNA1
SCHEMBL26871183 0.70 KDM4E (0.36) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008130569-A1 NOVEL PYRAZOLOPYRIMIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS SCHERING CORPORATION (US) 2008-10-30 — — WO disclosed
Send feedback